Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on December 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded up $0.35 during trading hours on Wednesday, hitting $51.80. 701,295 shares of the company’s stock were exchanged, compared to its average volume of 638,444. The firm has a market capitalization of $2.97 billion, a P/E ratio of -152.35, a price-to-earnings-growth ratio of 0.50 and a beta of 0.67. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $57.65. The business’s 50 day moving average is $47.73 and its 200-day moving average is $44.72.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million during the quarter, compared to the consensus estimate of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.69 earnings per share. As a group, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Waldron Private Wealth LLC acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $215,000. Wedge Capital Management L L P NC raised its position in shares of Supernus Pharmaceuticals by 12.2% during the fourth quarter. Wedge Capital Management L L P NC now owns 78,095 shares of the specialty pharmaceutical company’s stock worth $3,881,000 after purchasing an additional 8,514 shares during the period. CoreCap Advisors LLC lifted its holdings in shares of Supernus Pharmaceuticals by 2,643.7% during the 4th quarter. CoreCap Advisors LLC now owns 8,231 shares of the specialty pharmaceutical company’s stock valued at $409,000 after buying an additional 7,931 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Supernus Pharmaceuticals by 23.6% during the 4th quarter. SG Americas Securities LLC now owns 12,800 shares of the specialty pharmaceutical company’s stock worth $636,000 after acquiring an additional 2,447 shares during the period. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at about $1,434,000.

Insiders Place Their Bets

In other news, SVP Frank Mottola sold 20,000 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the transaction, the senior vice president owned 15,496 shares of the company’s stock, valued at $781,153.36. This represents a 56.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the sale, the vice president owned 14,508 shares in the company, valued at $644,735.52. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 8.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. TD Cowen boosted their target price on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Stifel Nicolaus lifted their target price on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday, September 30th. Finally, Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target for the company. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Supernus Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $61.60.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.